Subscribe to our Email Alerts

Investor Fact Sheet

Company Name: Amplia Therapeutics Limited (ACN 165 160 841)

Business Description:

Amplia Therapeutics Limited (ASX: ATX) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Innate has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).


Shares on Issue: 66,463,185
Options on Issue: 9,153,688 (at varying exercise prices and expiry dates)

Market Listings:

Australian Securities Exchange (ASX Code: ATX)


Directors:

Dr Warwick Tong, Chairman, Non-Executive Director
Dr John Lambert, CEO and Managing Director
Dr Robert Peach, Independent Non-Executive Director
Dr Christopher Burns, Non-Executive Director


Management:

Dr John Lambert, CEO and Managing Director
Jeff Carter, CFO
Dr Mark Devlin, Chief Scientific Advisor


Registered Office:

Level 29
55 Collins Street
Melbourne VIC 3000
Australia


Auditors:

Grant Thornton Audit Pty
GPO Box 4736
Melbourne 3001
Australia



Download: